Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Don Drakeman

Jan van de Winkel

Genmab A/S

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.

HBM Holdings Limited

SOTIO Biotech develops immunotherapies for cancer treatment, focusing on advancing safer and effective options through clinical development. The company self-describes as focusing on a broad pipeline addressing various solid tumor types.

SOTIO Biotech

Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage biopharmaceutical company focused on in-licensing, developing and commercializing oncology drug candidates in China, US, and the rest of the world.

Xynomic Pharmaceuticals Holdings, Inc.

We are an international biotech company committed to improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, our passionate, innovative, and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, we have formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, our vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.  We are united by our core values: a passion for innovation, determination, integrity, and working as one team and respecting each other. When you work at Genmab you'll be part of a warm, fun, dynamic community seeking out and embracing the opportunity to build new and bold futures within a rapidly growing biotech company. Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions, and execute; feel cared for and supported. In its totality, this makes working at Genmab an extra[not]ordinary experience. Established in 1999, we are headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S., and Tokyo, Japan.  For more information, please visit Genmab.com Disclaimer: http://bit.ly/GENDisclaimer 

Metric
Company Name	Genmab A/S	HBM Holdings Limited	SOTIO Biotech	Xynomic Pharmaceuticals Holdings, Inc.
Symbol	GMAB	2.14K
MSH ID	COM:GENMAB	COM:HARBOURBIOMED	COM:SOTIO	COM:XYNOMICPHARMA
Market	STOCKS	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Pharmaceuticals
Country	DK	CN	CZ	US
Stage		Series C	Venture Round	Series B
Employee Count	2.29K	177
Website	genmab.com	harbourbiomed.com	sotio.com	xynomicpharma.com
LinkedIn	genmab	harbour-biomed	sotio
Founders

Metric
Market Cap	16.48B	131.44M
Enterprise Value
Monthly Web Traffic		603	3.94K	1.52K
Web Traffic Growth		-0.14	-0.39	4.19
Valuation
Raised Capital		102.80M	316.57M

Metric
Revenue	2.33B	89.50M
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.30B	87.47M
EBITDA	928.30M	26.65M
Operating Income	753.54M	21.83M
Net Income	616.32M	22.80M
EPS	9.44	0.03
Diluted EPS	9.35	0.03
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.99	1.00
Operating Profit Margin	0.32	0.28
EBITDA Margin	0.40	0.30
Net Profit Margin	0.31	0.31
Return on Equity	0.18	0.21
Return on Assets	0.15	0.10
Return on Capital Employed	0.18	0.13

COM:GENMAB

Genmab A/S

Last Close

1,483.50

25/11 09:37

Market Cap

116.34B

Beta: -

Volume Today

13.98K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	28.94	-1.03
P/B Ratio	4.00	1.52
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	8.21	2.57
EV Multiple	23.86	12.92

Metric
Days Sales Outstanding	116.47
Days Payables Outstanding		61.85K
Days Inventory Outstanding	94.14	4.29K
Operating Cycle	201.66	4.34K
Cash Conversion Cycle	-1.92K	-536.87
Asset Turnover	0.49	0.39

Metric
Operating Cash Flow	1.05B
Free Cash Flow	991.89M
Cash Flow to Debt	9.58	0.32
Operating Cash Flow/Sales	0.45	0.29
Free Cash Flow Yield	0.05	-0.76

Metric
Cash & Equivalents	2.11B	140.32M
Accounts Receivable	112.87M
Inventory	8.07M	1
Goodwill
Debt to Capitalization	0.03	0.45
Debt to Assets	0.02	0.39
Current Ratio	11.38	2.79
Quick Ratio	13.32	3.44

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.14
R&D to Revenue	0.43	3.32
SG&A to Revenue		0.25